Psychotropic medications and HIV

Clinical Infectious Diseases

Volumn 42, Issue 9, 2006, Pages 1305-1310

  Thompson, Alex ^a   Silvermari, Benjamin ^a   Dzeng, Liz ^a   Treisman, Glenn ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPRENAVIR; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; ANXIOLYTIC AGENT; CYTOCHROME P450; DULOXETINE; EFAVIRENZ; ENFUVIRTIDE; ILLICIT DRUG; INDINAVIR; METHADONE; MIRTAZAPINE; MOOD STABILIZER; NEFAZODONE; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; AGRANULOCYTOSIS; ALCOHOL WITHDRAWAL; ANOREXIA; ANXIETY; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABUSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; INSOMNIA; LETHARGY; LIVER FAILURE; MANIA; MENTAL DISEASE; MOTOR DYSFUNCTION; ORTHOSTATIC HYPOTENSION; PANIC; PATIENT COMPLIANCE; PRIAPISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA;

ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 33646107163     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501454     Document Type: Article

References (43)

1. Angelino AF, Treisman GJ. Management of psychiatric disorders in patients infected with human immunodeficiency virus. Clin Infect Dis 2001; 33:847-56.
2. Hutton HE, Lyketsos CG, Zenilman JM, Thompson RE, Erbelding EJ. Depression and HIV risk behaviors among patients in a sexually transmitted disease clinic. Am J Psychiatry. 2004; 161:912-4.
3. Meade CS, Sikkema KJ. HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005; 25:433-57.
4. Bartlett JA. Addressing the challenges of adherence. J Acquir Immune Defic Syndr 2002;29(Suppl 1):S2-10.
5. Yun LW, Maravi M, Kobayashi JS, Barton PL, Davidson AJ. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquir Immune Defic Syndr 2005; 38:432-8.
6. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001; 58:721-8.
7. Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatry 2003; 160:547-54.
8. Thomson Micromedex. Micromedex healthcare series. Available at: http://www.thomsonhc.com. Accessed 1 July 2005.
9. Tsasis P. Adherence assessment to highly active antiretroviral therapy. AIDS Patient Care and STDs 2001; 15:109-15.
10. Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman D. Barriers to antiretroviral adherence among HIV-infected adults. AIDs Patient Care and STDs 2000; 14:47-58.
11. Barlow DH, Gorman JM, Shear MK, Woods SW Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized, controlled trial. JAMA 2000; 283:2529-36.
12. Van Balkom A, Bakker A, Spinhoven P, Blaauw B, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185: 510-6.
13. Otto MW, Deveney C. Cognitive-behavioral therapy and the treatment of panic disoder: efficacy and strategies. J Clin Psychiatry 2005; 66(Suppl 4):28-32.
14. Roy-Byrne PP, Craske MG, Stein MB, et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 2005; 62:290-8.
15. Tseng AL, Foisy M. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999; 33:461-73.
16. Himelhoch S, Moore RD, Treisman G, Gebo KA. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr 2004; 37:1457-63.
17. Caballero J, Nahata MC. Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV. Ann Pharmacother 2005; 39:141-5.
18. Quellet D, Hsu A, Qian J, et al. Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42:3107-12.
19. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001; 15:1281-5.
20. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003; 25: 1200-10.
21. Baker GB, Fang J, Sinha S, Coutts RT. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998; 22:325-33.
22. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3:13-37.
23. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol 2000; 20: 265-7.
24. Elliott AJ, Russo J, Bergam K, Claypoole K, Uldall KK, Roy-Byrne PP. Antidepressant efficacy in HIV-seropositive outpatients with major de-pressive disorder: an open trial of nefazodone. J Clin Psychiatry 1999; 60:226-31.
25. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43:414-22.
26. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004; 24:621-9.
27. Levin GM, Nelson LA, DeVane CL, Preston SL, Eisele G, Carson SW. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001; 35:62-71.
28. Currier MB, Molina G, Kato M. A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients. Psychosomatics 2003; 44:120-5.
29. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 2001; 29:100-2.
30. Park-Wyllie LY, Antoniou T. Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 2003; 17:638-40.
31. Elliott AJ, Uldall KK, Bergam K, Russo J, Claypoole K, Roy-Byrne PP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry 1998; 155: 367-72.
32. Rabkin JG, Rabkin R, Harrison W, Wagner G. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness. Am J Psychiatry 1994; 151:516-23.
33. Gannon RH, Anderson ML. Fluconazole-nortriptyline drug interaction (letter). Ann Pharmacother 1992; 26:1456-7.
34. Wynn G, Cozza K, Zapor M, Wortmann G, Armstrong S. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 2005; 46:79-87.
35. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002; 36:1598-613.
36. Liedtke M, Lockhart S, Rathbun RC. Anticonvulsant and antiretroviral interactions. Ann Pharmacother 2004; 38:482-9.
37. Hugen PW, Burger DM, Brinkman K, et al. Carbamazepine-indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000; 34:465-70.
38. Fernandez F, Levy JK, Samley HR, et al. Effects of methylphenidate in HIV-related depression: a comparative trial with desipramine. Int J Psychiatry Med 1995; 25:53-67.
39. Wagner GJ, Rabkin JG, Rabkin R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42:407-11.
40. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436-40.
41. Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus. Arch Intern Med 2001; 161:411-20.
42. Kresina TF, Flexner CW, Sinclair J, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18:757-70.
43. Braithwaite RS, McGinnis KA, Conigliaro J, et al. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol Clin Exp Res 2005; 29: 1190-7.